IBIO vs XLK
iBio, Inc. Common Stock (IBIO) versus Technology Select Sector SPDR® Fund (XLK) — a side-by-side from cached financials, not a winner call.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Technology Select Sector SPDR® Fund (XLK) common stock listed on US.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
XLK does not have a complete income-statement cache yet.
IBIO currently screens at market cap $13.4M. XLK currently screens at market cap $0.
Not investment advice. Open the IBIO and XLK stock pages for the full models.
Not investment advice.